InnoCare Pharma Limited
Other OTCTotal Valuation
InnoCare Pharma Limited carries a market capitalization of 2.32B, placing it among publicly traded companies globally. Its enterprise value stands at -6.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.32B |
| Enterprise Value | -6.13B |
Share Statistics
InnoCare Pharma Limited currently has 1.76B shares outstanding.
| Shares Outstanding | 1.76B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
InnoCare Pharma Limited maintains a current ratio of 3.82, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.00, indicating elevated leverage, while an interest coverage ratio of -25.53 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.82 |
| Quick Ratio | 3.57 |
| Debt / Equity | 20.00 |
| Debt / EBITDA | -2.16 |
| Interest Coverage | -25.53 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -4.74 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.99 |
Taxes
| Income Tax | 1.46M |
| Effective Tax Rate | N/A |
Stock Price Statistics
InnoCare Pharma Limited's stock has declined approximately -52.45399% over the past 52 weeks. The 50-day moving average sits at 1.55, while the 200-day moving average is 2.01.
| Beta (5Y) | N/A |
| 52-Week Price Change | -52.45399% |
| 50-Day Moving Average | 1.55 |
| 200-Day Moving Average | 2.01 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, InnoCare Pharma Limited generated 780.73M in revenue and converted that into -470.89M in net income, yielding earnings per share of -0.27. EBITDA reached -642.19M, while operating income came in at -642.19M.
| Revenue | 780.73M |
| Gross Profit | 668.22M |
| Operating Income | -642.19M |
| Pretax Income | -482.94M |
| Net Income | -470.89M |
| EBITDA | -642.19M |
| EBIT | -642.19M |
| Earnings Per Share (EPS) | -0.27 |
Balance Sheet
InnoCare Pharma Limited holds 7.55B in cash and equivalents against 1.39B in total debt, resulting in a net debt position of -5.59B. Total book value stands at -5.32B, with working capital of 5.96B providing operational flexibility.
| Cash & Cash Equivalents | 7.55B |
| Total Debt | 1.39B |
| Net Debt | -5.59B |
| Equity (Book Value) | -5.32B |
| Book Value Per Share | -2.99 |
| Working Capital | 5.96B |
Cash Flow
After subtracting -196.81M in capital expenditures, free cash flow totaled -196.81M - equivalent to -0.11 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -196.81M |
| Free Cash Flow | -196.81M |
| FCF Per Share | -0.11 |
Margins
InnoCare Pharma Limited operates with a gross margin of 85.59, reflecting its pricing power and cost economics. The operating margin of -82.26 and net profit margin of -60.31 provide insight into operational efficiency.
| Gross Margin | 85.59 |
| Operating Margin | -82.26 |
| Pretax Margin | -61.86 |
| Profit Margin | -60.31 |
| EBITDA Margin | -82.26 |
Dividends & Yields
The company's payout ratio of -0.06 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.00 |
| Dividend Yield | N/A |
| Payout Ratio | -0.06 |
| Shareholder Yield | N/A |
| FCF Yield | N/A |
Scores
InnoCare Pharma Limited posts an Altman Z-Score of -0.17, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.17 |